Triptolide and its pro-drug Minnelide target high-risk MYC amplified medulloblastoma in preclinical models

Overview of attention for article published in Journal of Clinical Investigation, June 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 16 news outlets
blogs: 2 blogs

twitter: 4 X users

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 2 posts from 2 blogs.

Drug developed for pancreatic cancer shows promise against most aggressive form of medulloblastoma

Health Medicine Network, 02 Aug 2024

Graphical abstract. Credit: Journal of Clinical Investigation (2024). DOI: 10.1172/JCI171136 A drug that was developed to treat…

Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

news-medical.net, 02 Aug 2024

A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.